Treatment outcomes of EGFR-TKI with or without locoregional brain therapy in advanced EGFR-mutant non-small cell lung cancer patients with brain metastases.
Do Mai LinhTran Huy ThinhNguyen-Van HieuNguyen Minh DucPublished in: Contemporary oncology (Poznan, Poland) (2023)
Epidermal growth factor receptor tyrosine kinase inhibitor therapy, with or without locoregional therapy, is effective for advanced EGFR-mutant NSCLC patients with brain metastases. Exon 19 deletion patients had better prognosis.
Keyphrases